Clinical Trials and Product Development - The company reported positive preliminary data from the Phase 1 clinical trial of ENTR-601-44, with muscle concentration detected in all six subjects in the 6 mg/kg dose cohort (mean of 53.8 ng/g) and mean target engagement as measured by exon skipping at 0.44%[104][108]. - The Phase 1 clinical trial included 32 healthy male volunteers across four cohorts, with doses of 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, and 6 mg/kg administered[106]. - The company plans to submit regulatory applications in Q4 2024 for ENTR-601-44 and ENTR-601-45, and in 2025 for ENTR-601-50, all targeting Duchenne muscular dystrophy[109][110]. Financial Performance and Revenue - Collaboration revenue for the three months ended September 30, 2024, was $19.6 million, a decrease of $24.2 million from $43.7 million in the same period of 2023[136]. - For the nine months ended September 30, 2024, collaboration revenue was $173.4 million, an increase of $86.2 million from $87.2 million in the same period of 2023[145]. - The net loss for the three months ended September 30, 2024, was $14.0 million, compared to a net income of $35.5 million in the same period of 2023, reflecting a change of $49.5 million[136]. - The company does not expect to generate revenue from product sales until successful completion of clinical development and regulatory approval[120]. Expenses and Cash Flow - Research and development expenses primarily consist of costs related to personnel, third-party agreements, and manufacturing processes, with a focus on neuromuscular program development[121][124]. - Research and development expenses increased to $31.3 million for the three months ended September 30, 2024, up by $9.1 million from $22.2 million in the same period of 2023[139]. - Total operating expenses for the nine months ended September 30, 2024, were $120.5 million, up by $25.3 million from $95.2 million in the same period of 2023[144]. - The company anticipates that research and development expenses will continue to increase as it advances its therapeutic candidates through clinical trials[140]. - Net cash used in operating activities was $10.0 million for the nine months ended September 30, 2024, compared to net cash provided of $143.8 million in the same period of 2023[154][157]. - Net cash used in investing activities was $81.2 million for the nine months ended September 30, 2024, compared to $157.4 million in the same period of 2023[158][159]. - Net cash provided by financing activities was $101.6 million for the nine months ended September 30, 2024, significantly up from $20.3 million in the same period of 2023[160][161]. Funding and Financial Position - As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $449.3 million, expected to fund operations into 2027[119]. - The company has raised over $850.0 million in gross proceeds from equity sales and the Vertex Agreement since inception[113]. - The accumulated deficit as of September 30, 2024, was $130.5 million, with expectations of continued operating losses and negative cash flows[114]. - The company expects to incur significant operating losses and negative cash flows for the foreseeable future as it advances its EEV Platform and therapeutic candidates[162]. - The company anticipates that its cash resources will be sufficient to fund operations into 2027 based on current operating plans[162]. Regulatory and Reporting Status - The company qualifies as an Emerging Growth Company (EGC) and intends to take advantage of exemptions under the JOBS Act, including reduced reporting requirements[171]. - The company will remain an EGC until the earliest of five years post-IPO, total annual gross revenues of $1.235 billion or more, or issuance of more than $1.0 billion in non-convertible debt[172]. - The company has reduced disclosure obligations regarding executive compensation as a smaller reporting company[173]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company[175]. - The company may present only two years of audited financial statements and related Management's Discussion and Analysis under EGC provisions[171].

Entrada Therapeutics Reports Third Quarter 2024 Financial Results – Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory filings for planned Phase 2 clinical trials for both ENTR-601-44 and ENTR-601-45 in Q4 2024 – – Vertex announced the completion of the single ascending dose (SAD) and the initiation of the multiple ascending dose (MAD) portions ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), is a clinicalstage biopharmaceutical company aiming to transform the l ...

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 138.46%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced earnings of $0.68, delivering a surprise of 278.95%. Over the last four quarters, the ...

Entrada Therapeutics, Inc. (TRDA) closed the last trading session at $16.17, gaining 14.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.33 indicates a 25.7% upside potential. However, an impressive consensus price target is not the only factor that indicates a potential upside in TRDA. This view is strengthened by the agreement among analysts that the company will report bet ...

Entrada Therapeutics, Inc. (TRDA) shares rallied 10.4% in the last trading session to close at $17.37. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.9% loss over the past four weeks. Last month, the company announced positive preliminary data from its phase I ENTR-601-44-101 study, which evaluated its lead pipeline candidate, ENTR-601-44, as a potential treatment for Duchenne Muscular Dystrophy. Treatment ...

BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinicalstage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that it has entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stoc ...

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding the expected closing of the offering and Entrada's anticipated use of the net proceeds from the offering constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate ...

– ENTR-601-44 demonstrated significant plasma concentration, muscle concentration and exon skipping, at levels that suggest the potential for a clinically meaningful starting dose in planned upcoming patient trials – "We are excited to present the first clinical data from our Duchenne franchise, led by ENTR-601-44. ENTR601-44 was well tolerated in healthy volunteers and we are pleased to see significant plasma concentration, muscle concentration and exon skipping. We achieved the goals of the ENTR-601-44-10 ...